This is a working overview of pentadecapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-26. Anything still debated is marked as such rather than presented as settled.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Freeze-dried cake or loose powder after lyophilization |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are less durable than the powder |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light; avoid repeated freeze-thaw cycles |
| Identity method | Electrospray mass spectrometry | Compared against the expected mass; paired with sequence or composition analysis |
| Purity method | Reverse-phase HPLC with ultraviolet detection | Reports main-peak percentage rather than peptide content by mass |
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
WHO suggests assessing workers' exposure in workplaces with methods similar to those used for the proposed specific occupational exposure limit (OEL) value of the MNM (conditional recommendation, low-quality evidence). Because there are no specific regulatory OEL values for MNMs in workplaces, WHO suggests assessing whether workplace exposure exceeds a proposed OEL value for the MNM. A list of proposed OEL values is provided in an annex of the guidelines. The chosen OEL should be at least as protective as a legally mandated OEL for the bulk form of the material (conditional recommendation, low-quality evidence). If specific OELs for MNMs are not available in workplaces, WHO suggests a step-wise approach for inhalation exposure with, first an assessment of the potential for exposure; second, conducting basic exposure assessment and third, conducting a comprehensive exposure assessment such as those proposed by the Organisation for Economic Cooperation and Development (OECD) or Comité Européen de Normalisation (the European Committee for Standardization, CEN) (conditional recommendation, moderate quality evidence). For dermal exposure assessment, WHO found that there was insufficient evidence to recommend one method of dermal exposure assessment over another. C. Control exposure to MNMs
Sherman (1930–2008), 12 US patents John Sherwood (died 2020), British physical chemist Nevil Vincent Sidgwick (1873–1952), English theoretical chemist, known for work in valency Osamu Shimomura (1928–2018), 2008 Nobel Prize in Chemistry Hideki Shirakawa (1936–2026), 2000 Nobel Prize in Chemistry Alexander Shulgin (1925–2014), pioneer researcher in Psychopharmacology and Entheogens Salimuzzaman Siddiqui (1897–1994), Pakistani chemist, pioneer in natural products chemistry Oktay Sinanoglu (1935–2015), Turkish chemist Joseph H. Simons (1897–1983), U.S. chemist, discoverer of fluorocarbons, used in gaseous diffusion of Uranium for Manhattan project Jens Christian Skou (1918–2018), 1997 Nobel Prize in Chemistry Richard Smalley (1943–2005), 1996 Nobel Prize in Chemistry Michael Smith (1932–2000), 1993 Nobel Prize in Chemistry Ascanio Sobrero (1812–1888), Italian chemist, discoverer of nitroglycerin Frederick Soddy (1877–1956), British chemist, 1921 Nobel Prize in Chemistry Susan Solomon (born 1956), American atmospheric chemist Ernest Solvay (1838–1922), Belgian chemist and industrialist S.P.L. Sørensen (1868–1939), Danish chemist Gabor A.
Lithium is a teratogen, which can cause birth defects in a small number of newborns. Case reports and several retrospective studies have demonstrated possible increases in the rate of a congenital heart defects (CHDs) including Ebstein's anomaly if taken during the first trimester of pregnancy. The risk is dose-dependent: in the 2017 AMX registry study, the relative risk of "any malformations" is 1.11 in those taking no more than 600 mg of lithium carbonate daily, 1.60 in those taking 601–900 mg daily, and 3.22 in those taking more than 900 mg daily. The first two numbers do not indicate a statistically significant association. In a 2018 meta-analysis, there was a statistically significant 62% increase (95% CI: 12%–133%) in congenital malformations in general, but not for cardiac malformations specifically. Exposure during any part of the pregnancy is associated with a slight but statistically significant increase in the risks of preterm birth and of a larger-than-usual baby at birth. Lithium is effective for preventing relapse during and after pregnancy. As the risks of stopping Lithium can be significant, patients are sometimes recommended to stay on this medicine while pregnant. Careful weighing of the risks and benefits should be made in consultation with a psychiatric physician. The relatively low teratogenic risk of lithium allows such a choice. The decision should be made before the start of pregnancy, as there is no reason for stopping lithium once the pregnancy has started.
== History == GCLS was established in Geneva in 2024 with a focus on formal education in longevity science, an interdisciplinary field drawing on ageing biology, preventive medicine, public health and related disciplines. Dominik Thor has served as president of the institution. Luiza Spiru, a physician and professor whose work includes gerontology, geriatrics and longevity medicine, has been involved in its academic programmes. The institution subsequently expanded its postgraduate and professional education and developed international scientific activities. In February 2025, GCLS partnered with Dubai Science Park to hold a Longevity Science Semester Symposium in Dubai. Dubai Science Park reported that the two-day meeting brought together participants from healthcare, life sciences, academic and public-sector organizations. In 2026, GCLS announced an academic partnership with Ovidius University of Constanța for a research doctorate in medicine with a specialization in longevity sciences. Ovidius University is identified as the degree-awarding institution, while GCLS serves as the international academic partner. GCLS provides postgraduate and professional education in longevity science and longevity medicine. Its portfolio includes a master's-level programme in longevity science, continuing medical education and professional training for physicians, and postgraduate study in peptide therapeutics.
hypoxanthine (I) A naturally occurring, non-canonical purine nucleobase that is used in some RNA molecules and pairs with standard nucleobases in a phenomenon known as wobble base pairing. Its nucleoside form is known as inosine, which is the reason it is commonly abbreviated with the letter I in sequence reads.
Sources: en.wikipedia.org
== Treatment == There is no cure for aromatic L-amino acid decarboxylase deficiency, but medical and multidisciplinary treatment can relieve some of the symptoms. Individuals will require physiotherapy, occupational therapy, and speech and language therapy. Some will need enteral feeding (for example, a gastrostomy or jejunostomy) due to difficulties with chewing and swallowing. Various medications can help compensate for the missing neurotransmitters. Dopamine agonists such as rotigotine or pramipexole and monoamine oxidase inhibitors such as selegiline are commonly used. Individuals may also need to take a range of other medications to control dyskinesia, constipation and other symptoms. In July 2021, results of a small gene therapy phase I study reported observation of dopamine restoration on seven participants between 4 and 9 years old. In July 2022, the gene therapy product eladocagene exuparvovec was approved in the European Union for use in patients aged 18 months or older.
MI6 reportedly infiltrated an Al Qaeda website and replaced the instructions for making a pipe bomb with the recipe for making cupcakes. In October 2010, Iain Lobban, the director of the Government Communications Headquarters (GCHQ), said the UK faces a "real and credible" threat from cyber attacks by hostile states and criminals and government systems are targeted 1,000 times each month, such attacks threatened the UK's economic future, and some countries were already using cyber assaults to put pressure on other nations. On 12 November 2013, financial organizations in London conducted cyber war games dubbed "Waking Shark 2" to simulate massive internet-based attacks against bank and other financial organizations. The Waking Shark 2 cyber war games followed a similar exercise in Wall Street.
=== Mic–Mu === Leonor Michaelis (1875–1949). German biochemist at the Rockefeller Institute of Medical Research, known for early work on enzyme kinetics. He developed biochemistry in Japan. He studied quinones, and used this knowledge to develop a method for producing a perm (hairstyle). Friedrich Miescher (1844–1895). Swiss physician and biologist at Leipzig University, the first to isolate DNA. Kenneth R. Miller (born 1948), American evolutionary biologist and author of Finding Darwin's God César Milstein FRS (1927–2002). Argentinian-British biochemist at the University of Cambridge, known for developing the use of monoclonal antibodies. Nobel Prize in Physiology or Medicine (1984). Foreign associate Natl. Acad. Sci. USA. María Teresa Miras Portugal (1948–2021), Spanish biochemist, pharmacist and molecular biologist. Peter D. Mitchell FRS (1920–1992). British biochemist at Glynn Research, known for the theory of chemiosmosis. Nobel Prize in Chemistry (1978). Foreign associate Natl. Acad. Sci. USA. John Keith Moffat (b. 1943), British biophysicist at Argonne National Laboratory known for work on time-resolved crystallography. Catherine Anne Money (b. 1940), Australian biochemist known for revolutionizing leather production Jacques Monod FRS (foreign member) (1910–1976). French biochemist and microbiologist at the Pasteur Institute, known for many discoveries and for the theory of allostery. His philosophical book Chance and Necessity has been influential. Nobel Prize in Physiology or Medicine (1965).
==== Desiccation stress ==== Desiccation (drought) stress is defined as conditions where water becomes the growth limiting factor. MAAs have been reportedly found in high concentrations in many microorganisms exposed to drought stress. Particularly cyanobacteria species that are exposed to desiccation, UV radiation and oxidation stress have been shown to possess MAA's in an extracellular matrix. However it has been shown that MAAs do not provide sufficient protection against high doses of UV radiation.
=== RNAi pathway for gene knockdown === Gene knockdown is a method used to reduce the expression of an organism's specific genes. This is accomplished by using the naturally occurring process of RNAi. This gene knockdown technique uses a double-stranded siRNA molecule that is synthesized with a sequence complementary to the gene of interest. The RNAi cascade begins once the Dicer enzyme starts to process siRNA. The end result of the process leads to degradation of mRNA and destroys any instructions needed to build certain proteins. Using this method, researchers are able to decrease (but not completely eliminate) the expression of a targeted gene. Studying the effects of this decrease in expression may show the physiological role or impact of the targeted gene products.
Sources: en.wikipedia.org
=== Facilitates the quaternary structure === The enzyme cytochrome c oxidase, also known as Complex IV, is a large transmembrane protein complex found in mitochondria and bacteria. It is the last enzyme in the respiratory electron transport chain located in the inner mitochondrial or bacterial membrane. It receives an electron from each of four cytochrome c molecules, and transfers them to one oxygen molecule, converting molecular oxygen to two molecules of water. Complex IV has been shown to require two associated CL molecules in order to maintain its full enzymatic function. Cytochrome bc1 (Complex III) also needs cardiolipin to maintain its quaternary structure and functional role. Complex V of the oxidative phosphorylation machinery also displays high binding affinity for CL, binding four molecules of CL per molecule of complex V.
On June 7, after winning the election, Ford said that the "very first item" on his agenda would be to cancel the federal carbon tax and provincial cap-and-trade programs in order to prevent motorists from being "gouged at the pumps". According to a June 28, 2018 article in The Economist, Ontario, with "Canada's second-highest public debt per person and a growing budget deficit", Ford's "poleaxing of cap and trade" would result in C$2.8bn worth of pollution permits owned by companies that could result in lawsuits. The article said that Ontario would lose C$2bn a year from the sale of pollution permits under its cap-and-trade program, which represents 1.3% of Ontario's revenue. In November 2018, the Ford government announced that it was eliminating three provincial watchdog groups, including the Environmental Commissioner of Ontario (ECO), to cut costs. Then Environmental Commissioner of Ontario (ECO), Dianne Saxe, had just submitted her 4-volume, 339-page 2018 Environmental Protection Report, entitled "Back to Basics, to the Legislative Assembly of Ontario. Saxe was a "vocal critic" of the Ford government's "actions on climate change"—"their vow to fight a federal carbon tax, pulling out of more than 700 renewable energy contracts and moving to end the Ontario Green Energy Act." Bill 57, also known as the Restoring Trust, Transparency and Accountability Act transferred the Environmental Commissioner Officer's duties to the Auditor General of Ontario.
== Cerebrospinal fluid; == the following analysis of the format - ( Normal Order Name; Designation in the laboratory; Laboratory), can be performed on the sample material in the title of the heading above
=== Pharmacodynamics === Esketamine is approximately twice as potent an anesthetic as racemic ketamine. The possibility that arketamine may be more effective than esketamine has been suggested by some researchers. Esketamine inhibits dopamine transporters eight times more than arketamine. This increases dopamine activity in the brain. At doses causing the same intensity of effects, esketamine is generally considered to be more pleasant by patients. Patients also generally recover mental function more quickly after being treated with pure esketamine, which may be a result of the fact that it is cleared from their system more quickly. However, this observation contrasts with findings that arketamine exhibits antidepressant effects without causing psychotomimetic side effects. Unlike arketamine, esketamine does not bind significantly to sigma receptors. Esketamine increases glucose metabolism in the frontal cortex, while arketamine decreases glucose metabolism in the brain. This difference may be responsible for the fact that esketamine generally has a more dissociative or hallucinogenic effect while arketamine is reportedly more relaxing. However, another study found no difference between racemic ketamine and esketamine on the patient's level of vigilance. Interpretation of this finding is complicated by the fact that racemic ketamine is 50% esketamine.
Sources: en.wikipedia.org
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.
It describes the share of the chromatographic signal belonging to the main peak, not the mass fraction of peptide in the vial. Water, counter-ions such as acetate or trifluoroacetate, and residual solvents account for part of the weight of a lyophilized lot. Peptide content by mass is a separate measurement and is often reported alongside purity.
Mass spectrometry is the primary check, because the measured mass can be compared with the expected value for the fifteen-residue chain. Sequence analysis or amino acid composition provides an independent confirmation. Purity testing alone does not establish identity, since a mixture of unrelated short peptides can still produce a clean-looking chromatogram.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.